By comparison, depletion of FOXO1 by sgFOXO1 resulted in a marked delay in MCL progression and a survival benefit as evidenced by the diminished tumor burden and spleen enlargement (Supplemental Figure 7L), confirming that FOXO1 inhibition could suppress MCL progression in vivo. Here, FOXO1 is linked to mantle cell lymphoma.